Xilio Therapeutics Inc
Company Profile
Business description
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
Contact
828 Winter Street
Suite 300
WalthamMA02451
USAT: +1 857 524-2466
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
73
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,786.70 | 13.10 | 0.15% |
| CAC 40 | 7,557.31 | 0.85 | -0.01% |
| DAX 40 | 23,649.30 | 150.97 | 0.64% |
| Dow JONES (US) | 43,386.84 | 404.41 | 0.94% |
| FTSE 100 | 8,735.60 | 16.85 | 0.19% |
| HKSE | 24,357.21 | 31.81 | 0.13% |
| NASDAQ | 20,167.91 | 194.36 | 0.97% |
| Nikkei 225 | 40,215.36 | 630.78 | 1.59% |
| NZX 50 Index | 12,544.91 | 64.86 | 0.52% |
| S&P 500 | 6,141.02 | 48.86 | 0.80% |
| S&P/ASX 200 | 8,556.80 | 6.00 | 0.07% |
| SSE Composite Index | 3,443.62 | 4.83 | -0.14% |